Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial

Full text
Martinez, Rafael C. R. [1] ; Franceschini, Silvio A. [2] ; Patta, Maristela C. [3] ; Quintana, Silvana M. [3] ; Gomes, Bruna C. [1] ; De Martinis, Elaine C. P. [1] ; Reid, Gregor [4, 5, 6, 7]
Total Authors: 7
[1] Univ Sao Paulo, Dept Anal Clin Toxicol & Bromatol, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Ribeirao Preto - Brazil
[2] Sistema Interno Saude Univ Sao Paulo, BR-14055370 Ribeirao Preto - Brazil
[3] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Obstet & Ginecol, BR-14040030 Ribeirao Preto - Brazil
[4] Canadian Res & Dev Ctr Probiot, Lawson Hlth Res Inst, London, ON N6A 4V2 - Canada
[5] Univ Western Ontario, Dept Microbiol, London, ON N6A 5C1 - Canada
[6] Univ Western Ontario, Dept Immunol, London, ON N6A 5C1 - Canada
[7] Univ Western Ontario, Dept Surg, London, ON N6A 5C1 - Canada
Total Affiliations: 7
Document type: Journal article
Source: Canadian Journal of Microbiology; v. 55, n. 2, p. 133-138, FEB 2009.
Web of Science Citations: 73

Bacterial vaginosis (BV) is the most prevalent vaginal infection worldwide and is characterized by depletion of the indigenous lactobacilli. Antimicrobial therapy is often ineffective. We hypothesized that probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 might provide an adjunct to antimicrobial treatment and improve cure rates. Sixty-four Brazilian women diagnosed with BV were randomly assigned to receive a single dose of tinidazole (2 g) supplemented with either 2 placebo capsules or 2 capsules containing L. rhamnosus GR-1 and L. reuteri RC-14 every morning for the following 4 weeks. At the end of treatment (day 28), the probiotic group had a significantly higher cure rate of BV (87.5%) than the placebo group (50.0%) (p = 0.001). In addition, according to the Gram-stain Nugent score, more women were assessed with ``normal'' vaginal microbiota in the probiotic group (75.0% vs. 34.4% in the placebo group; p = 0.011). This study shows that probiotic lactobacilli can provide benefits to women being treated with antibiotics for an infectious condition. (AU)

FAPESP's process: 06/06595-2 - Effect of use of probiotic lactic acid bacteria on the vaginal microbiota of patients with bacterial and fungal infections
Grantee:Elaine Cristina Pereira de Martinis
Support type: Regular Research Grants